Interesting Images99mTc Tamoxifen for Imaging Estrogen Receptor Expression in Metastatic Breast Cancer PatientChhabra, Anupriya MSc*; Shukla, Jaya PhD*; Kumar, Rajender MD*; Laroiya, Ishita MD†; Vatsa, Rakhee PhD*; Bal, Amanjit MD‡; Singh, Gurpreet MD†; Mittal, Bhagwant Rai MD*Author Information From the Departments of *Nuclear Medicine †General Surgery ‡Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Received for publication July 17, 2019; revision accepted October 16, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Jaya Shukla, PhD, Department of Nuclear Medicine and PET, Nehru Hospital, Ground Flr, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. E-mail: email@example.com. Online date: January 30, 2019 Clinical Nuclear Medicine: March 2020 - Volume 45 - Issue 3 - p 225-227 doi: 10.1097/RLU.0000000000002900 Buy Metrics Abstract Estrogen receptor–expressing breast cancer exhibits better prognosis due to responsiveness to antiestrogen treatment. Therefore, knowledge of the estrogen receptor status of a tumor is an important prognostic and predictive indicator in breast cancer. We present noninvasive imaging of estrogen receptors with 99mTc tamoxifen that can identify the active tumor and approachable sites for biopsy. It may help in selection of patients for hormone replacement therapy and in assessment of receptor status in recurrent disease and also in response evaluation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.